Litcius/Paper detail

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

Tingyan Shi, Jianqing Zhu, Yanling Feng, Dongsheng Tu, Yuqin Zhang, Zhang Ping, Huixun Jia, Xiao Huang, Yunlang Cai, Sheng Yin, Rong Jiang, Wenjuan Tian, Wen Gao, Jihong Liu, Huijuan Yang, Xi Cheng, Rongyu Zang

2021The Lancet Oncology228 citationsDOI

Topics & Concepts

MedicineChemotherapyOvarian cancerInternal medicineOpen labelOncologyRandomized controlled trialSurgeryCancerOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyIntraperitoneal and Appendiceal Malignancies
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial | Litcius